What can we learn from epigenetics in the year 2009?

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 284-292

  Jüngel, Astrid ^a   Ospelt, Caroline ^a   Gay, Steffen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Epigenetics; Histone deacetylases; Methylation; Microrna; Rheumatoid arthritis; Sirtuins, sumoylation

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; SIRTUIN; VALPROIC ACID;

ACETYLATION; AUTOIMMUNE DISEASE; DEACETYLATION; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION; HUMAN; METHYLATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SUMOYLATION;

ACETYLATION; ARTHRITIS, RHEUMATOID; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RHEUMATIC DISEASES; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 77950202883     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283389641     Document Type: Review

References (86)

1. Huber LC, Stanczyk J, Jungel A, et al. Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum 2007; 56:3523-3531.
2. Kwon HS, Ott M. The ups and downs of SIRT1. Trends Biochem Sci 2008; 33:517-525.
3. Brandl A, Heinzel T, Kramer OH. Histone deacetylases: salesmen and customers in the posttranslational modification market. Biol Cell 2009; 101:193-205.
4. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373:659-672.
5. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:578-582.
6. Karberg S. Switching on epigenetic therapy. Cell 2009; 139:1029-1031.
7. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138:101 9-1031.
8. DiekerJ, MullerS. Epigenetic histone code and autoimmunity. Clin Rev Allergy Immunol 2009. [Epub ahead of print]
9. van der Maarel SM. Epigenetic mechanisms in health and disease. Ann Rheum Dis 2008; 67 (Suppl 3):iii97-iii100.
10. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33:3-11.
11. Trenkmann M, Brock M, Ospelt C, Gay S. Epigenetics in rheumatoid arthritis. Clin Rev Allergy Immunol 2009. [Epub ahead of print]
12. Hirst M, Marra MA. Epigenetics and human disease. Int J Biochem Cell Biol 2009; 41:136-146.
13. Huber LC, Brock M, Hemmatazad H, et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007; 56:1087-1093.
14. Chung YL, Lee MY, Wang AJ, et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8:707-717.
15. Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004; 50: 3365-3376.
16. Nasu Y, Nishida K, Miyazawa S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008; 16:723-732.
17. Hemmatazad H, Maciejewska Rodrigues H, Huber LC, et al. Anti-destructive effects of trichostatin A (TSA) are partly mediated through altered expression of histone deacetylase 7 (HDAC7). Arthritis Rheum 2009; 60:S274.
18. Hemmatazad H, Maciejewska-Rodrigues H, Gay RE, et al. Inflammatory cytokines induce global chromatin acetylation in RASF. Arthritis Rheum 2008; 58:S911.
19. Dokmanovic M, Perez G, Xu W, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007; 6:2525-2534.
20. Halili MA, Andrews MR, Sweet MJ, et al. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9:309-319.
21. Horiuchi M, Morinobu A, Chin T, et al. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009; 36:1580-1589.
22. Hong S, Derfoul A, Pereira-Mouries L, et al. A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J 2009; 23:3539-3552.
23. Higashiyama R, Miyaki S, Yamashita S, et al. Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. Mod Rheumatol 2010; 20:11-17.
24. Wang X, Song Y, Jacobi JL, et al. Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors 2009; 27:40-49.
25. Urbich C, Rossig L, KaluzaD, etal. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood 2009; 113:5669-5679.
26. Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006; 126:321-334.
27. Saouaf SJ, Li B, Zhang G, et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009; 87:99-104.
28. Wang L, de Zoeten EF, Greene MI, et al. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 2009; 8:969-981.
29. Neidhart M, Jungel A, Ospelt C, et al. Deficient expression of interleukin-10 receptor alpha chain in rheumatoid arthritis synovium: limitation of animal models of inflammation. Arthritis Rheum 2005; 52:3315-3318.
30. Schulze-Tanzil G, Zreiqat H, Sabat R, et al. Interleukin-10 and articular cartilage: experimental therapeutical approaches in cartilage disorders. Curr Gene Ther 2009. [Epub ahead of print]
31. Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10:92-100.
32. Migliorini P, Pratesi F, Tommasi C, et al. The immune response to citrullinated antigens in autoimmune diseases. Autoimmun Rev 2005; 4:561-564.
33. Anzilotti C, Pratesi F, Tommasi C, et al. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 2010; 9:158-160.
34. Denis H, Deplus R, Putmans P, etal. Functional connection between deimina-tion and deacetylation of histones. Mol Cell Biol 2009; 29:4982-4993.
35. Lavu S, BossO, Elliott PJ, etal. Sirtuins: novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008; 7:841-853.
36. Smith BC, Hallows WC, Denu JM. Mechanisms and molecular probes of sirtuins. Chem Biol 2008; 15:1002-1013.
37. Sequeira J, Boily G, Bazinet S, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 2008; 314:3069-3074.
38. Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 2009; 12:431-437.
39. Gabay OH, Gagarina V, Lee EJ, etal. Decreased levels of Sirt1 in OA articular cartilage are associated with an increase in MMP-3,-13 and apoptosis. Arthritis Rheum 2009; 60:S488.
40. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 2009; 9:886-896.
41. Mehra A, BakerCL, Loros JJ, etal. Posttranslational modifications in circadian rhythms. Trends Biochem Sci 2009; 34:483-490.
42. Cavadini G, Petrzilka S, Kohler P, etal. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA 2007; 104:12843-12848.
43. Hashiramoto A, Yamane T, Tsumiyama K, et al. Mammalian clock gene cryptochrome regulates arthritis via proinflammatory cytokine TNF-{alpha}. J Immunol 2010; 184:1560-1565.
44. Nakahata Y, Sahar S, Astarita G, et al. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 2009; 324:654-657.
45. Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 2009; 324:651-654.
46. Brentano F, Schorr O, Ospelt C, et al. Pre-B cell colony-enhancing factor/ visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56:2829-2839.
47. Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/ visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008; 83:804-816.
48. Courties G, Brentano F, Niederer F, etal. RNA interference-mediated gene therapy of PBEF reduces the severity of collagen-induced arthritis in mice. Ann Rheum Dis 2009; 68 (Suppl 3):194.
49. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009; 8:712-715.
50. Niederer F, Brentano F, Ospelt C, et al. Expression of sirtuins in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60:S52.
51. Yeung F, Hoberg JE, Ramsey CS, etal. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23:2369-2380.
52. Salminen A, Kaarniranta K. SIRT1: regulation of longevity via autophagy. Cell Signal 2009; 21:1356-1360.
53. Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11:959-967.
54. Yang Y, Fu W, Chen J, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol 2007; 9:1253-1262.
55. Franz JK, Pap T, Hummelt KM, et al. Expression of sentrin, a novel antiapop-totic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000; 43:599-607.
56. Meinecke I, Cinski A, Baier A, et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci USA 2007; 104:5073-5078.
57. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002; 21:2383-2396.
58. Takayama K, Ishida K, Matsushita T, et al. SIRT1 regulation of apoptosis of human chondrocytes. Arthritis Rheum 2009; 60:2731-2740.
59. Dvir-Ginzberg M, Gagarina V, Lee EJ, et al. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phos-phoribosyltransferase. J Biol Chem 2008; 283:36300-36310.
60. Kurowska-Stolarska M, Distler JH, Jungel A, et al. Inhibitor of DNA binding/ differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis Rheum 2009; 60:3663-3675.
61. Distler JH, Wenger RH, Gassmann M, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004; 50:10-23.
62. Giatromanolaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1alpha and-2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5:R193-R201.
63. Dioum EM, Chen R, Alexander MS, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009; 324:1289-1293.
64. Guarente L Cell biology. Hypoxic hookup. Science 2009; 324:1281-1282.
65. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007; 21:2644-2658.
66. Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 2008; 7:2117-2122.
67. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol 2009; 5:332-340.
68. Brandes RP. Activating SIRT1: a new strategy to prevent atherosclerosis? Cardiovasc Res 2008; 80:163-164.
69. Menghini R, Casagrande V, Cardellini M, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009; 120:1524-1532.
70. Ouyang J, Gill G. SUMO engages multiple corepressors to regulate chromatin structure and transcription. Epigenetics 2009; 4:440-444.
71. Maciejewska-Rodrigues H, Karouzakis E, Strietholt S, et al. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. J Autoimmun (in press).
72. Zhao S, Long H, Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol 2009. [Epub ahead of print]
73. Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 2010; 20:170-179.
74. Karouzakis E, Gay RE, Michel BA, et al. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60:3613-3622.
75. Karouzakis E, Gay RE, Gay S, et al. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol 2009; 5:266-272.
76. Liu Y, Chen Y, Richardson B. Decreased DNA methyltransferase levels contribute to abnormal gene expression in 'senescent' CD4(+)CD28(\) T cells. Clin Immunol 2009; 132:257-265.
77. Griffiths EA, Gore SD. MicroRNA: mIR-ly regulators of DNMT? Blood 2009; 113:6269-6270.
78. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113:6411-6418.
79. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007; 61 (5 Pt 2):24R-29R.
80. StanczykJ, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58:1001-1009.
81. This is the first report about microRNAs in RA, showing that the inflammatory milieu alters microRNA expression profiles in resident cells of the affected joints.
82. Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008; 58:1284-1292.
83. Stanczyk Feldges J, Karouzakis E, Jungel A, et al. Mir-203 regulates the expression of IL-6 and matrixmetalloproteinase (MMP)-1 in RA synovial fibroblasts. Arthritis Rheum 2009; 60:S706.
84. Nakamachi Y, Kawano S, Takenokuchi M, et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 2009; 60:1294-1304.
85. Alsaleh G, Suffert G, Semaan N, et al. Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide- activated rheumatoid fibroblast-like synoviocytes. J Immunol 2009; 182:5088-5097.
86. Nagata Y, Nakasa T, Mochizuki Y, et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis Rheum 2009; 60:2677-2683.